IRIS
FASANO, MASSIMO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.789
EU - Europa 3.428
AS - Asia 2.910
SA - Sud America 597
Continente sconosciuto - Info sul continente non disponibili 321
AF - Africa 49
OC - Oceania 4
Totale 11.098
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.710
CN - Cina 1.100
IE - Irlanda 930
SG - Singapore 721
UA - Ucraina 714
SE - Svezia 482
BR - Brasile 473
RU - Federazione Russa 429
FR - Francia 322
VN - Vietnam 303
HK - Hong Kong 246
IN - India 219
TR - Turchia 188
FI - Finlandia 186
IT - Italia 104
DE - Germania 102
GB - Regno Unito 69
AR - Argentina 56
CA - Canada 29
MX - Messico 24
ID - Indonesia 23
BD - Bangladesh 22
AT - Austria 21
EU - Europa 21
ZA - Sudafrica 19
EC - Ecuador 17
IQ - Iraq 15
CZ - Repubblica Ceca 14
PK - Pakistan 13
CO - Colombia 12
VE - Venezuela 11
NL - Olanda 10
UY - Uruguay 10
BE - Belgio 9
ES - Italia 9
EG - Egitto 8
SY - Repubblica araba siriana 8
JM - Giamaica 7
PY - Paraguay 7
BG - Bulgaria 6
JP - Giappone 6
NP - Nepal 6
SA - Arabia Saudita 6
AE - Emirati Arabi Uniti 5
CL - Cile 5
KE - Kenya 5
PL - Polonia 5
TT - Trinidad e Tobago 5
SV - El Salvador 4
UZ - Uzbekistan 4
AZ - Azerbaigian 3
CH - Svizzera 3
CR - Costa Rica 3
IR - Iran 3
KZ - Kazakistan 3
PE - Perù 3
RS - Serbia 3
TH - Thailandia 3
TN - Tunisia 3
AU - Australia 2
BO - Bolivia 2
CI - Costa d'Avorio 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
EE - Estonia 2
GT - Guatemala 2
KR - Corea 2
LB - Libano 2
LT - Lituania 2
MA - Marocco 2
MY - Malesia 2
NZ - Nuova Zelanda 2
RO - Romania 2
SN - Senegal 2
AL - Albania 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
ET - Etiopia 1
GA - Gabon 1
GH - Ghana 1
GR - Grecia 1
GY - Guiana 1
HN - Honduras 1
IL - Israele 1
JO - Giordania 1
KG - Kirghizistan 1
LC - Santa Lucia 1
ML - Mali 1
MM - Myanmar 1
OM - Oman 1
PH - Filippine 1
PR - Porto Rico 1
PS - Palestinian Territory 1
PT - Portogallo 1
UG - Uganda 1
Totale 10.798
Salva come PNG Salva come JPEG
Città #
Dublin 928
San Jose 618
Jacksonville 506
Dearborn 317
Singapore 300
Nyköping 298
Nanjing 281
Chandler 249
Hong Kong 243
Ashburn 164
Beijing 157
Wilmington 137
Santa Clara 128
Dong Ket 117
Dallas 115
Council Bluffs 112
Princeton 104
Nanchang 102
Lauterbourg 98
New Providence 83
Moscow 80
San Mateo 79
Helsinki 78
Ho Chi Minh City 71
The Dalles 61
Shenyang 60
Hebei 52
Kunming 51
Tianjin 44
Hanoi 41
Munich 38
Columbus 37
Jiaxing 37
Ann Arbor 35
New York 35
Changsha 34
Ningbo 29
São Paulo 27
Jinan 26
Los Angeles 25
Stevenage 24
Des Moines 23
Phoenix 23
Zhengzhou 21
Guangzhou 19
Hilden 19
Hangzhou 17
Nuremberg 16
Shanghai 16
Lanzhou 15
Turku 14
Ankara 13
Brno 13
Taizhou 13
Redwood City 12
Rio de Janeiro 12
Vienna 12
Pune 10
Atlanta 9
Montevideo 9
Quảng Ngãi 9
Woodbridge 9
Agrolândia 8
Brasília 8
Chengdu 8
Foggia 8
Guarulhos 8
Johannesburg 8
Brussels 7
Haiphong 7
London 7
Orange 7
San Francisco 7
Baghdad 6
Belo Horizonte 6
Biên Hòa 6
Boardman 6
Boston 6
Campinas 6
Chicago 6
Guayaquil 6
Hefei 6
Kingston 6
Mexico City 6
Montreal 6
Norwalk 6
Ribeirão Preto 6
Tokyo 6
Toronto 6
Al Mansurah 5
Augusta 5
Bari 5
Bogotá 5
Buenos Aires 5
Cape Town 5
Changchun 5
Curitiba 5
Frankfurt am Main 5
Medellín 5
Paris 5
Totale 6.559
Salva come PNG Salva come JPEG
Nome #
2-years effectiveness and safety of tenofovir in 302 NUC-naïve patients with chronic hepatitis B: a multicenter European study in clinical practice 218
2-years effectiveness and safety of tenofovir in 302 NUC-naïve patients with chronic hepatitis B: a multicenter European study in clinical practice 188
2-YEAR EFFECTIVENESS AND SAFETY OF TENOFOVIR IN 302 NUC-NAIVE PATIENTS WITH CHRONIC HEPATITIS B: A MULTICENTER EUROPEAN STUDY IN CLINICAL PRACTICE 171
5-year Entecavir in NUC-naïve, field practice patients with CHB showed excellent viral suppression and safety but no prevention of HCC 157
Bone and kidney toxicity induced by nucleotide analogues in patients affected by HBV-related chronic hepatitis: a longitudinal study. 153
Nucleios(t)ide analogue discontinuation is not associated with increased rates of HBsAg loss in chronic hepatitis B 140
A MODEL TO PREDICT SUCCESS FOLLOWING PEG-INTERFERON AND RIBAVIRIN THERAPY FOR PATIENTS WITH HCV-1 INFECTION 136
Hepatitis C virus clearance after direct-acting antivirals in cirrhotic patients by stages of liver impairment: the ITAL-C network study 136
5-YEAR ENTECAVIR TREATMENT IN NUC-NAIVE, FIELD-PRACTICE PATIENTS WITH CHRONIC HEPATITIS B SHOWED EXCELLENT VIRAL SUPPRESSION AND SAFETY PROFILE BUT NO PREVENTION OF HCC IN CIRRHOTICS 134
An a priori prediction model of response to peginterferon plus ribavirin dual therapy in naïve patients with genotype 1 chronic hepatitis C. 134
Entecavir monotherapy improves renal function in patients developing renal side effects during long-term tenofovir treatment without compromising virological response: a multicenter real-life study in 103 patients 132
Flares during long-term entecavir therapy in chronic hepatitis B 129
Acute Hepatitis C in Haemodialysis patients: natural course and response to IFNα-monotherapy 128
A proposito di epatite B. News da EASL 2008. 127
Entecavir monotherapy in 418 NUC-naïve patients with chronic hepatitis B from field practice: high efficacy and favourable safety profile over 3 years of treatment 125
preliminary Data From the Study of Coagulative Profile of HIV infected Individuals suggest a role for point mutations in the Gene in protein S deficiency in Individuals undergoing Higly Antiretroviral therapy 125
EFFICACY AND SAFETY OF LONG-TERM THERAPY WITH ENTECAVIR (ETV) OR TENOFOVIR (TDF) IN PATIENTS WITH HBV-RELATED CIRRHOSIS 124
Four years of tenofovir monotherapy for NUC naive field practice European patients suppresses HBV replication in most patients with a favorable renal safety profile but does not prevent HCC in patients with or without cirrhosis 123
.Long-term lamivudine treatment in patients with HBeAg negative chronic hepatitis B: how long? 121
Patients with HDV infection and advanced fibrosis/cirrhosis present a high but predictable risk of developing hepatocellular carcinoma 121
Chronic hepatitis B: Advances in treatment. 120
Acute hepatitis C: A 24-week course of pegylated interferon alpha-2b versus a 12-week course of pegylated interferon alpha-2b alone or with ribavirin 119
Interim analysis of the Italian Master-Entas cohort study: entecavir effectiveness in field practice for chronic hepatitis B 119
Selection of HCV-1 patients with chronic hepatitis who might benefit from current standard of therapy with peg-interferon and ribavirin 118
PREDICTION OF HBeAg SEROCONVERSION IN HBeAg-POSITIVE CHRONIC HEPATITIS B PATIENTS TREATED WITH ENTECAVIR USING ALT AND PLATELET COUNT: RESULTS FROM A LARGE EUROPEAN MULTI-CENTER STUDY 117
Analisi di costo-efficacia del trattamento dell’epatite cronica B con analoghi nucleos(t)idici nella pratica clinica 114
ENTECAVIR MONOTHERAPY IN 418 NUC-NAIVE PATIENTS WITH CHRONIC HEPATITIS B FROM FIELD PRACTICE: HIGH EFFICACY AND FAVORABLE SAFETY PROFILE OVER 3 YEARS OF TREATMENT 114
Longitudinal PAGE-B Scores Predict the Risk of Hepatocellular Carcinoma and other Adverse Clinical Outcomes in Chronic Hepatitis B Patients on Entecavir Therapy 114
HBsAg loss is enough to discontinue long-term nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B patients in real practice 113
Epatite acuta C in un’ampia coorte di pazienti: fattori di rischio ed evoluzione 112
Epatite acuta C a risoluzione spontanea: evoluzione a lungo termine 112
An open, randomized, multicentre trial to evaluate efficacy and safety of a 24 week-course of Peg-interferon α-2b versus a 12 week-course of Peg-Interferon α-2b alone or plus ribavirin in patients with acute hepatitis C 111
Cost-effectiveness of Tenofovir in the treatment of patients with chronic hepatitis B: data from literature 108
Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B 108
Impact of adding raltegravir to antiretroviral regimens in patients with blood viral suppression but persistent seminal viral shedding 107
Tenofovir suppressed viral suppression in most field practice, treatment-naive patients with CHB followed for 3 years in a multicenter European study 106
Interim analysis of the Italian Master-Entas cohort study: entecavir can improve liver function in patients with chronic hepatitis B and liver cirrhosis 106
Detection of in vivo hepatitis B virus surface antigen mutations-a comparison of four routine screening assays 106
Adefovir resistance patterns in patients with lamivudine resistant chronic hepatitis B 105
Malattie causate da Elminti 105
Acute hepatitis C: clinical and laboratory diagnosis, course of the disease, treatment. 105
Reply. 104
Entecavir for NUC-naïve chronic hepatitis B patients in clinical practice: long-term effectiveness from large multicenter cohort study in 376 patients 104
Come trattare il paziente con non risposta o risposta virologica parziale 104
Risposta a lungo termine alla monoterapia con lamivudina in pazienti con epatite cronica B, HBeAg negativa: è opportuno cambiare? 104
Genotypic resistance to adefovir (ADV) in patients with lamivudine (LAM) resistant chronic hepatitis B 104
HCV genotype 1 subtypes (1a and 1b): similarities and differences in clinical features and therapeutic outcome 103
Nuove strategie di trattamento 103
ENTECAVIR FOR NUC-NAÏVE CHRONIC HEPATITIS B PATIENTS IN CLINICAL PRACTICE: LONG-TERM EFFECTIVENESS FROM A LARGE MULTICENTER COHORT STUDY IN 376 PATIENTS 102
THE ITALIAN ENTAS COHORT STUDY: ENTECAVIR EFFECTIVENESS IN NAïVE AND TREATMENT EXPERIENCED PATIENTS WITH CHRONIC HEPATITIS B 101
Prediction of hepatocellular carcinoma in entecavir treated patients: results from 744 chronic hepatitis B patients in European Multicenter Study (VIRGIL) 100
Long-term response to lamivudine monotherapy in patients with HBeAg-negative chronic hepatitis B: to change or not to change? 98
Entecavir monotherapy in 418 NUC-naïve patients with chronic hepatitis B from field practice: high efficacy and favourable safety profile over 3 years of treatment 98
Selection of HCV-1 patients with chronic hepatitis who might benefit from current standard of therapy with peg-interferon and ribavirin. 19th International Symposium on Hepatitis C Virus and Related Viruses 98
Definizione delle resistenze e metodiche di laboratorio 98
Efficacia e tollerabilità della monoterapia con Entecavir (ETV) in pazienti con epatite cronica B 98
ENTECAVIR EFFECT ON LIVER FUNCTION IN FIELD PRACTICE: INTERIM ANALYSIS OF THE ITALIAN Master-Entas COHORT STUDY OF PATIENTS WITH CHRONIC HEPATITIS B 97
Tenofovir monotherapy suppressed viral suppression in most field practice, treatment-naive patients with chronic hepatitis B followed for 3 years in a multicenter European study 96
La genetica dei virus epatitici: implicazioni cliniche e terapeutiche 96
Risposta virologica e resistenza ad Adefovir dipivoxil (ADV) in pazienti con Epatite Cronica B resistente alla Lamivudina (LAM) 96
Mutations selected during lamivudine therapy may predispose to adefovir resistance 95
Risposta alla terapia con Adefovir Dipivoxil (ADV) in pazienti con Epatite Cronica B, resistenti alla Lamivudina 95
An open, randomized, multicentre trial to evaluate efficacy and safety of a 24 week-course of Peg-Interferon α-2b versus a 12-week-course of Peg-Interferon α-2b alone or plus ribavirin in patients with Acute Hepatitis C 94
Efficacia e sicurezza della terapia a lungo termine con Entecavir (ETV) o Tenofovir (TDF) in pazienti con cirrosi epatica HBV correlata 94
Diagnostic value of alpha-fetoprotein for early hepatocellular carcinoma diagnosis in cirrhotic HBV patient successfully treated with nucleos(t)ide analogues - a case report 94
Clinical outcomes in patients with hepatitis D, cirrhosis and persistent hepatitis B virus replication, and receiving long-term tenofovir or entecavir. 94
Current Concepts on Management of Chronic Hepatitis BPractical Management of Chronic Viral Hepatitis 93
Long-term follow up of patients with acute hepatitis C and spontaneous resolution 93
Effectiveness of entecavir in field practice: interim analysis of the Italian MASTER-ENTAS cohort study of patients with chronic hepatitis B 93
Resistance profile of entecavir in patients with chronic hepatitis B 93
Entecavir effectiveness in naïve and NUC experienced patients: Interim analysis of the ENTAS cohort study of patients with chronic hepatitis B 91
Entecavir treatment for NUC naïve, field practice patients with chronic hepatitis B: excellent viral suppression and safety profile over 5 years of treatment 90
Maintained viral suppression and excellent safety profile of Entecavir monotherapy in 418 NUC-naïve patients with chronic hepatitis B: a 4-year field practice, multicenter study 90
Early hepatic flares during ETV treatment are rare and do not require treatment adaptation in chronic hepatitis B without cirrhosis 90
Dalla terapia di combinazione Lamivudina+Adefovir alla monoterapia con Tenofovir in pazienti con Epatite Cronica B, HBeAg-negativa: risultati di efficacia e sicurezza 90
Long-Term HDV-RNA Suppression – HBsAg Clearance in Chronic Hepatitis D Following Interferon Therapy 89
Effectiveness of entecavir for NUC-naïve, HBeAg-negative chronic hepatitis B patients in clinical practice: a 2-year multicenter cohort study in 311 patients 89
Studio multicentrico, randomizzato per valutare l’efficacia e la sicurezza di un ciclo di monoterapia con Peg-Interferone alfa-2b della durata di 24 settimane verso un trattamento di 12 settimane di Peg-interferone alfa-2b in monoterapia o in associazione alla ribavirina in pazienti con epatite acuta C 89
No beneficial of long-term analogue treatment on the clinical outcome of patients with chronic hepatitis Delta and advanced liver disease. A case-control study. 88
Epatite B e Immigrazione 87
HBV e migranti: risultati di uno studio multicentrico SIMIT 87
Risk of hepatocellular carcinoma in chronic hepatitis B patients treated with nucleos(t)ide analogues and long-term virological suppression 87
Epatite acuta C in pazienti in trattamento emodialitico periodico. 86
Four years of tenofovir monotherapy for NUC naïve field practice European patients suppresses HBV replication in most patients with a favorable renal safety profile but does not prevent HCC in patients with or without cirrhosis 84
Entecavir for NUC-naïve chronic hepatitis B patients in clinical practice: long-term effectiveness from large multicenter cohort study in 376 patients 84
Efficacia e tollerabilità a lungo termine della monoterapia con entecavir in pazienti con Epatite Cronica B 84
Tenofovir monotherapy for naïve patients with chronic hepatitis B: a multicenter European study in clinical practice in 302 patients followed for 30 months 83
Lack of association between IL28B variants and HBsAg clearance after interferon treatment 83
HBV and immigrants: a SIMIT multicenter cross-sectional study 82
Entecavir effectiveness in naïve and NUC experienced patients: Interim analysis of the ENTAS cohort study of patients with chronic hepatitis B 82
HBSAG LOSS IS ENOUGH TO DISCONTINUE LONG-TERM NUCLEOS(T)IDE ANALOGUE THERAPY IN HBEAG-NEGATIVE CHRONIC HEPATITIS B PATIENTS IN REAL PRACTICE? 81
Entecavir in “real-life”: risultati dello studio VIRGIL 80
ENTECAVIR EFFECTIVENESS IN DAILY CLINICAL PRACTICE, INTERIM ANALYSIS OF THE ITALIAN Master-Entas COHORT STUDY OF PATIENTS WITH CHRONIC HEPATITIS B 79
Genotypic resistance to adefovir (ADV) in patients with lamivudine (LAM) resistant chronic hepatitis B 79
Intraoperative ultrasound: “Alternative eye” in lymph nodal dissection in non-small cell lung cancer 77
Effectiveness and safety of therapy simplification from Lamivudine + Adefovir to Tenofovir monotherapy in virologically suppressed HBeAg-negative chronic hepatitis B patients 76
Effectiveness of entecavir for nuc-naive HBeAg-negative chronic hepatitis B patients in clinical practice: a 2-year multicenter cohort study in 311 patients 75
Terapia a lungo termine con Lamivudina in pazienti con epatite cronica B anti-HBe positiva: quando sospendere? 75
Effectiveness and safety of tenofovir disoproxil fumarate in field practice: a multicenter European cohort study of 302 NUC-naïve patients with chronic hepatitis B 74
Disparities in tuberculosis diagnostic delays between native and migrant populations in Italy: A multicenter study 74
Totale 10.508
Salva come PNG Salva come JPEG
Categoria #
all - tutte 54.547
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 54.547
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022465 0 0 0 9 73 32 15 54 66 68 16 132
2022/20231.856 237 91 58 76 53 138 2 126 1.021 17 21 16
2023/2024189 34 10 7 13 18 41 26 8 3 3 1 25
2024/20251.331 68 3 9 14 8 187 201 74 384 63 180 140
2025/20262.674 152 142 458 569 70 66 471 241 200 119 50 136
2026/2027595 39 179 143 234 0 0 0 0 0 0 0 0
Totale 11.098